ANI Pharmaceuticals Stock (NASDAQ:ANIP)
Previous Close
$68.12
52W Range
$52.50 - $70.00
50D Avg
$62.28
200D Avg
$59.80
Market Cap
$1.48B
Avg Vol (3M)
$307.72K
Beta
0.49
Div Yield
-
ANIP Company Profile
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, injectables, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract development and manufacturing of pharmaceutical products for other companies. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. The company was incorporated in 2001 and is headquartered in Baudette, Minnesota.
ANIP Performance
Revenue Breakdown
Revenue Breakdown by Product/Service
| Product/Service | Dec 24 | Dec 23 | Dec 22 |
|---|---|---|---|
| Unapproved Products | $22.40M | - | - |
| Sales of rare disease pharmaceutical products | - | $112.12M | $41.69M |
| Sales of established brand pharmaceutical products | - | $105.25M | $39.46M |
| Sales of generic pharmaceutical products | - | $269.45M | $210.12M |
| Other | - | - | $693.00K |
| Sales of contract manufactured products | - | - | $4.30M |
| Royalties from licensing agreements | - | - | $5.37M |
| Product development services | - | - | $2.95M |
Fiscal year ends in Dec 24 | Currency in USD
Peer Comparison
| Ticker | Company |
|---|---|
| PROC | Procaps Group S.A. |
| AMPH | Amphastar Pharmaceuticals, Inc. |
| PBH | Prestige Consumer Healthcare Inc. |
| ALKS | Alkermes plc |
| IRWD | Ironwood Pharmaceuticals, Inc. |
| NBIX | Neurocrine Biosciences, Inc. |
| COLL | Collegium Pharmaceutical, Inc. |
| RDY | Dr. Reddy's Laboratories Limited |
| INCR | InterCure Ltd. |
| PAHC | Phibro Animal Health Corporation |
| PCRX | Pacira BioSciences, Inc. |